SUPPLEMENTARY MATERIAL

PRISMA 2009 checklist .................................................................2
Search terms – OVID (Embase, Global Health, MEDLINE) .....................4
Search terms – Scopus ................................................................6
Search terms – Web of science..........................................................7
Agreement between reviewers during screening of titles and abstracts.........8
Risk of bias assessment (ROBINS-I)................................................9
IS DIABETES ASSOCIATED WITH MALARIA AND MALARIA SEVERITY? A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES
Carrillo-Larco RM, Fernandez-Altez C, Ugarte-Gil C.

PRISMA 2009 checklist

| Section/topic | # | Checklist item | Reported on page # |
|---------------|---|----------------|-------------------|
| TITLE         |   |                |                   |
| Title         | 1 | Identify the report as a systematic review, meta-analysis, or both. | 01 |
| ABSTRACT      | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | Abstract (with background, methods, results and conclusions) |
| INTRODUCTION  |   |                |                   |
| Rationale     | 3 | Describe the rationale for the review in the context of what is already known. | Introduction (lines 1-16) |
| Objectives    | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | Introduction (lines 17-18) |
| METHODS       |   |                |                   |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | Methods (study design) |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | Methods (selection criteria) |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | Methods (search strategy) |
| Search        | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | Methods (search strategy) |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | Methods (data collection) |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | Methods (data collection) |
| Data items    | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | Methods (data collection) |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | Methods (data collection) |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | Methods (data collection) |
### IS DIABETES ASSOCIATED WITH MALARIA AND MALARIA SEVERITY? A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES
Carrillo-Larco RM, Fernandez-Altez C, Ugarte-Gil C.

| Section/topic | # | Checklist item | Reported on page # |
|---------------|---|----------------|-------------------|
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$) for each meta-analysis. | Methods (data collection) |

| Section/topic | # | Checklist item | Reported on page # |
|---------------|---|----------------|-------------------|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | NA |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | NA |

### RESULTS

| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | Results (search strategy) |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | Results (study characteristics) |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | Results (risk of bias) |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | Results (diabetes and malaria) |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | NA |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | NA |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | NA |

### DISCUSSION

| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | Discussion (summary of evidence) |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | Discussion (limitations) |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | Discussion (conclusion) |

### FUNDING

| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | Funding |

From: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

3
IS DIABETES ASSOCIATED WITH MALARIA AND MALARIA SEVERITY? A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES
Carrillo-Larco RM, Fernandez-Altez C, Ugarte-Gil C.

### Search terms – OVID (Embase, Global Health, MEDLINE)

|   |                                                                                      |
|---|--------------------------------------------------------------------------------------|
| 1 | "Malaria".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 2 | "Malaria, Vivax".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 3 | "Malaria, Falciparum".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 4 | 1 or 2 or 3                                                                         |
| 5 | "malaria".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 6 | Plasmodi*.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 7 | "falciparum".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 8 | "ovale".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 9 | "malariae".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 10 | "vivax".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 11 | "knowlesi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 12 | "vinckeia".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 13 | "aegyptensis".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 14 | "berghei".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 15 | "bergei".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 16 | "chabaudi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 17 | "inopinatum".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 18 | "yoelli".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 19 | "bucki".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 20 | "cercopitheci".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 21 | "coatneyi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 22 | "coulangesi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 23 | "cynomolgi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 24 | "eyelesi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 25 | "fieldi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 26 | "foleyi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 27 | "Girardi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 28 | "georgesi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 29 | "gonderi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 30 | "hylobatid".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 31 | "inui".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 32 | "jefferyi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 33 | "lemuris".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 34 | "reichenowi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 35 | "rodhaini".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 36 | "sandoshami".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 37 | "semnopithecus".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
IS DIABETES ASSOCIATED WITH MALARIA AND MALARIA SEVERITY? A SYSTEMATIC REVIEW OF
OBSERVATIONAL STUDIES
Carrillo-Larco RM, Fernandez-Altez C, Ugarte-Gil C.

|   |   |
|---|---|
| 44 | "silvaticum".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 45 | "simiovale".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 46 | "simium".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 47 | "uilenbergi".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 48 | "youngei".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 49 | 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 |
| 50 | 4 or 49 |
| 51 | "Diabetes Mellitus".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 52 | "Diabetes Mellitus, Type 2".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 53 | "Diabetes Mellitus, Type 1".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, bt, id, cc, nm, kf, px, rx, ui, sy] |
| 54 | exp animals/ not humans.sh. |
| 55 | 51 or 52 or 53 |
| 56 | 50 and 55 |
| 57 | 56 not 54 |
| 58 | remove duplicates from 57 |
IS DIABETES ASSOCIATED WITH MALARIA AND MALARIA SEVERITY? A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES
Carrillo-Larco RM, Fernandez-Altez C, Ugarte-Gil C.

Search terms – Scopus

( ALL ( malaria ) OR ALL ( malaria AND vivax ) OR ALL ( malaria AND falciparum ) OR ALL ( plasmodi* ) OR ALL ( falciparum ) OR ALL ( ovale ) OR ALL ( malariae ) OR ALL ( vivax ) OR ALL ( knowlesi ) OR ALL ( vinckeia ) OR ALL ( vinckwei ) OR ALL ( aegyptensis ) OR ALL ( berghei ) OR ALL ( bergei ) OR ALL ( chabaudi ) OR ALL ( inopinatum ) OR ALL ( yoelli ) OR ALL ( bouillize ) OR ALL ( brasilianum ) OR ALL ( bucki ) OR ALL ( cercopithec ) OR ALL ( coatneyi ) OR ALL ( coulangesi ) OR ALL ( cynomolg ) OR ALL ( eylesi ) OR ALL ( fieldi ) OR ALL ( foleyi ) OR ALL ( girardi ) OR ALL ( georgesi ) OR ALL ( gonderi ) OR ALL ( hylobatid ) OR ALL ( inui ) OR ALL ( jefferyi ) OR ALL ( joyeuxi ) OR ALL ( lemuris ) OR ALL ( percygarnhami ) OR ALL ( petersi ) OR ALL ( reichenowi ) OR ALL ( rodhaini ) OR ALL ( sandoshami ) OR ALL ( semnopithec ) OR ALL ( silvaticum ) OR ALL ( simiovale ) OR ALL ( simium ) OR ALL ( uilenbergi ) OR ALL ( youngei ) ) AND ( ALL ( diabetes AND mellitus ) OR ALL ( type 2 diabetes AND mellitus ) OR ALL ( type 1 diabetes AND mellitus ) ) AND NOT DBCOLL ( medl ) AND ( LIMIT-TO ( DOCTYPE, "ar " ) ) AND ( LIMIT-TO ( SUBJAREA, "MEDI " ) )
IS DIABETES ASSOCIATED WITH MALARIA AND MALARIA SEVERITY? A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES
Carrillo-Larco RM, Fernandez-Altez C, Ugarte-Gil C.

Search terms – Web of science

((TS=(malaria) OR TS=(malaria vivax) OR TS=(malaria falciparum) OR TS=(Plasmodi*) OR TS=(falciparum) OR TS=(ovale) OR TS=(malariae) OR TS=(vivax) OR TS=(knowlesi) OR TS=(vinckeia) OR TS=(vinckwei) OR TS=(aegyptensis) OR TS=(bergheni) OR TS=(bergei) OR TS=(chabaudi) OR TS=(inopinatum) OR TS=(yoelli) OR TS=(bouillize) OR TS=(brasilianum) OR TS=(bucki) OR TS=(cercopithecii) OR TS=(coatneyi) OR TS=(coulangesii) OR TS=(cynomolgus) OR TS=(eacesi) OR TS=(fieldi) OR TS=(foleyi) OR TS=(Girardi) OR TS=(georgesi) OR TS=(gondrei) OR TS=(hylobatid) OR TS=(inui) OR TS=(jefferyi) OR TS=(joyeuxi) OR TS=(lemuris) OR TS=(percygarnhami) OR TS=(petersi) OR TS=(reichenowi) OR TS=(rodhaini) OR TS=(sandoshami) OR TS=(semnopithecii) OR TS=(silvaticum) OR TS=(simiovale) OR TS=(simium) OR TS=(silbenbergi) OR TS=(youngei)) AND (TS=(diabetes mellitus) OR TS=(type 2 diabetes mellitus) OR TS=(type 1 diabetes mellitus))) AND DOCUMENT TYPES: (Article)
Agreement between reviewers during screening of titles and abstracts

| CA-F | Included | Excluded | Total | Conflict |
|------|----------|----------|-------|----------|
| RMCL | 7        | 2        | 9     | 3        |
| Included | 1        | 1982     | 1983  |          |
| Excluded |          |          |       |          |
| Total   | 8        | 1984     | 1992  |          |
| Agreement | 0.9985   |          |       |          |
| Chance, Yes | 0.0000   |          |       |          |
| Chance, No | 0.9915   |          |       |          |
| Chance agreement | 0.0000 |          |       |          |
| Kappa | 0.9985   |          |       |          |

Agreement = (included by both + excluded by both)/total
Chance, Yes = (Yes/Total, for rater1)* (Yes/Total for rater 2)
Chance, No = (No/Total, for rater1)* (No/Total for rater 2)
Chance agreement = Chance Yes * Chance No
Kappa = (Agreement - Chance agreement) / 1 - Chance agreement
| Risk of bias assessment (ROBINS-I) | Danquah I, et al. | Wyss K, et al. | Khuu D, et al. |
|----------------------------------|------------------|----------------|----------------|
| **Is there potential for confounding of the effect of intervention in this study?** | Y | Y | Y |
| **Was the analysis based on splitting participants’ follow up time according to intervention received?** | N | N | N |
| **Did the authors use an appropriate analysis method that controlled for all the important confounding domains?** | Y | Y | Y |
| **If Y/PY to 1.4: Were confounding domains that were controlled for measured validly and reliably by the variables available in this study?** | NI | PY | PY |

| Bias due to selection of participants into the study | Serious risk of bias | Serious risk of bias | Serious risk of bias |
|--------------------------------------------------|----------------------|----------------------|----------------------|
| **Was selection of participants into the study (or into the analysis) based on participant characteristics observed after the start of intervention (interpreted as exposure)?** | Y | Y | Y |
| **If Y/PY to 2.1: Were the post- intervention variables that influenced selection likely to be associated with intervention?** | Y | Y | Y |
| **If Y/PY to 2.2: Were the post intervention variables that influenced selection likely to be influenced by the outcome or a cause of the outcome?** | Y | Y | Y |
| **Do start of follow-up and start of intervention coincide for most participants?** | PN | PN | PN |
| **If Y/PY to 2.2 and 2.3, or N/PN to 2.4: Were adjustment techniques used that are likely to correct for the presence of selection biases?** | PN | PN | PN |
IS DIABETES ASSOCIATED WITH MALARIA AND MALARIA SEVERITY? A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES
Carrillo-Larco RM, Fernandez-Altez C, Ugarte-Gil C.

| Risk of bias judgement | Critical risk of bias | Critical risk of bias | Critical risk of bias |
|------------------------|-----------------------|-----------------------|-----------------------|
| Bias in classification of interventions |                       |                       |                       |
| 3.1 Were intervention (interpreted as comparison) groups clearly defined? | Y | Y | Y |
| 3.2 Was the information used to define intervention groups recorded at the start of the intervention? | Y | Y | Y |
| 3.4 Could classification of intervention status have been affected by knowledge of the outcome or risk of the outcome? | N | N | N |

| Bias due to deviations from intended |                       |                       |                       |
|-------------------------------------|-----------------------|-----------------------|-----------------------|
| 5.1 Were outcome data available for all, or nearly all, participants? | Y | Y | Y |
| 5.2 Were participants excluded due to missing data on intervention status? | Y | Y | Y |
| 5.3 Were participants excluded due to missing data on other variables needed for the analysis? | NI | NI | NI |
| 5.4 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Are the proportion of participants and reasons for missing data similar across interventions? | NI | NI | NI |
| 5.5 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Is there evidence that results were robust to the presence of missing data? | NI | NI | NI |

| Risk of bias judgement |                       |                       |                       |
|------------------------|-----------------------|-----------------------|-----------------------|
| Bias due to deviations from intended |                       |                       |                       |
| 5.1 Were outcome data available for all, or nearly all, participants? | Y | Y | Y |
| 5.2 Were participants excluded due to missing data on intervention status? | Y | Y | Y |
| 5.3 Were participants excluded due to missing data on other variables needed for the analysis? | NI | NI | NI |
| 5.4 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Are the proportion of participants and reasons for missing data similar across interventions? | NI | NI | NI |
| 5.5 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Is there evidence that results were robust to the presence of missing data? | NI | NI | NI |
### Bias in measurement of outcomes

|   | Question                                                                 | Study 1 | Study 2 | Study 3 |
|---|---------------------------------------------------------------------------|---------|---------|---------|
| 6.1 | Could the outcome measure have been influenced by knowledge of the intervention received? | N       | N       | N       |
| 6.2 | Were outcome assessors aware of the intervention (interpreted as exposure) received by study participants? | NI      | NI      | NI      |
| 6.3 | Were the methods of outcome assessment comparable across intervention groups? | Y       | Y       | Y       |
| 6.4 | Were any systematic errors in measurement of the outcome related to intervention received? | NI      | NI      | NI      |

#### Risk of bias judgement

|   | Risk of bias judgement |
|---|------------------------|
|   | Moderate risk of bias  |

### Bias in selection of the reported result

|   | Question                                                                 | Study 1 | Study 2 | Study 3 |
|---|---------------------------------------------------------------------------|---------|---------|---------|
| 7.1 | Is the reported effect estimate likely to be selected, on the basis of the results, from... | N       | N       | N       |
| 7.2 | ... multiple outcome measurements within the outcome domain?              | N       | N       | N       |
| 7.3 | ... multiple analyses of the intervention-outcome relationship?          | N       | N       | N       |
| 7.4 | ... different subgroups?                                                 | N       | N       | N       |

#### Risk of bias judgement

|   | Risk of bias judgement |
|---|------------------------|
|   | Moderate risk of bias  |

### Judgement

|   | Critical risk of bias |
|---|-----------------------|
|   | Critical risk of bias |
|   | Critical risk of bias |